Advertisement

Topics

Lundbeck and Takeda receive Complete Response Letter from the FDA for Trintellix (vortioxetine) sNDA

21:23 EDT 22 Jun 2017 | Topix

Takeda and Lundbeck are disappointed, but we believe in the strength of the data and plan to continue discussions with the FDA on potential paths forward. The companies remain committed to the depression community and Trintellix as a treatment option for adult patients living with depression, including those who suffer from cognitive dysfunction as part of this disease.

Original Article: Lundbeck and Takeda receive Complete Response Letter from the FDA for Trintellix (vortioxetine) sNDA

NEXT ARTICLE

More From BioPortfolio on "Lundbeck and Takeda receive Complete Response Letter from the FDA for Trintellix (vortioxetine) sNDA"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...